FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103188542> ?p ?o ?g. }

• W2103188542 abstract "Trastuzumab has been widely used for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer for more than a decade. However, reports on the involvement of HER2 downregulation in trastuzumab’s mechanism of action are inconsistent. The aim of this study is to investigate if the dependence of trastuzumab-mediated cancer cell HER2 downregulation on immune effector cells represents a novel mechanism of action for trastuzumab. HER2 expression was evaluated by Western blotting, flow cytometry, and real-time polymerase chain reaction (PCR) in cell lysates from co-cultures of multiple cancer cell lines with peripheral blood mononuclear cells (PBMCs) in the presence or absence of trastuzumab. The engagement of immune cells by trastuzumab through Fc gamma receptors (FcγRs) was tested using three trastuzumab variants with compromised or no Fc (fragment crystallizable) functions and FcγRs blocking experiments. The engagement of immune cells by trastuzumab in HER2 downregulation was also evaluated in in vivo mouse xenograft tumor models. HER2 downregulation of cancer cells by trastuzumab occurred only when trastuzumab was actively engaged with immune cells and cancer cells, as demonstrated consistently in co-cultures of cancer cell lines with PBMCs and in vivo mouse xenograft tumor models. We further demonstrated that HER2 downregulation in cancer cells by immune-cell-engaged trastuzumab was at the transcriptional level, not through the HER2 degradation pathway. Activation of signal transducer and activator of transcription 1 (STAT1) in cancer cells by the increased interferon gamma (IFN-γ) production in immune cells played an important role in downregulating HER2 in cancer cells upon engagement of immune cells by trastuzumab. Furthermore, HER2 downregulation in cancer cells induced by trastuzumab engagement of immune cells was correlated with the antibody’s antitumor efficacy in vivo. This study reveals that engagement of immune effector cells by trastuzumab induces HER2 downregulation in HER2-expressing cancer cells, which represents a new function of immune cells in trastuzumab-mediated antitumor efficacy and serves as a novel mechanism of action for trastuzumab. Our results imply that HER2 downregulation in cancer cells treated by trastuzumab may predict active engagement of immune effector cells in tumor microenvironment." @default.
• W2103188542 created "2016-06-24" @default.
• W2103188542 creator A5006123417 @default.
• W2103188542 creator A5008880709 @default.
• W2103188542 creator A5026356376 @default.
• W2103188542 creator A5031371352 @default.
• W2103188542 creator A5052731834 @default.
• W2103188542 creator A5080559983 @default.
• W2103188542 date "2014-04-01" @default.
• W2103188542 modified "2023-10-16" @default.
• W2103188542 title "Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation" @default.
• W2103188542 cites W1891363500 @default.
• W2103188542 cites W1971267920 @default.
• W2103188542 cites W1978941237 @default.
• W2103188542 cites W1988104771 @default.
• W2103188542 cites W1988610380 @default.
• W2103188542 cites W1994097025 @default.
• W2103188542 cites W2014390504 @default.
• W2103188542 cites W2019590981 @default.
• W2103188542 cites W2027542837 @default.
• W2103188542 cites W2036450767 @default.
• W2103188542 cites W2039609199 @default.
• W2103188542 cites W2059411043 @default.
• W2103188542 cites W2066471812 @default.
• W2103188542 cites W2081424327 @default.
• W2103188542 cites W2087524953 @default.
• W2103188542 cites W2102049853 @default.
• W2103188542 cites W2107022635 @default.
• W2103188542 cites W2107277218 @default.
• W2103188542 cites W2107426197 @default.
• W2103188542 cites W2128402413 @default.
• W2103188542 cites W2133105825 @default.
• W2103188542 cites W2141346487 @default.
• W2103188542 cites W2143738177 @default.
• W2103188542 cites W2144405588 @default.
• W2103188542 cites W2146944629 @default.
• W2103188542 cites W2160068811 @default.
• W2103188542 doi "https://doi.org/10.1186/bcr3637" @default.
• W2103188542 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4053225" @default.
• W2103188542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24693969" @default.
• W2103188542 hasPublicationYear "2014" @default.
• W2103188542 type Work @default.
• W2103188542 sameAs 2103188542 @default.
• W2103188542 citedByCount "40" @default.
• W2103188542 countsByYear W21031885422014 @default.
• W2103188542 countsByYear W21031885422015 @default.
• W2103188542 countsByYear W21031885422016 @default.
• W2103188542 countsByYear W21031885422017 @default.
• W2103188542 countsByYear W21031885422018 @default.
• W2103188542 countsByYear W21031885422019 @default.
• W2103188542 countsByYear W21031885422020 @default.
• W2103188542 countsByYear W21031885422021 @default.
• W2103188542 countsByYear W21031885422022 @default.
• W2103188542 countsByYear W21031885422023 @default.
• W2103188542 crossrefType "journal-article" @default.
• W2103188542 hasAuthorship W2103188542A5006123417 @default.
• W2103188542 hasAuthorship W2103188542A5008880709 @default.
• W2103188542 hasAuthorship W2103188542A5026356376 @default.
• W2103188542 hasAuthorship W2103188542A5031371352 @default.
• W2103188542 hasAuthorship W2103188542A5052731834 @default.
• W2103188542 hasAuthorship W2103188542A5080559983 @default.
• W2103188542 hasBestOaLocation W21031885421 @default.
• W2103188542 hasConcept C104317684 @default.
• W2103188542 hasConcept C121608353 @default.
• W2103188542 hasConcept C126322002 @default.
• W2103188542 hasConcept C127561419 @default.
• W2103188542 hasConcept C203014093 @default.
• W2103188542 hasConcept C2779786085 @default.
• W2103188542 hasConcept C502942594 @default.
• W2103188542 hasConcept C530470458 @default.
• W2103188542 hasConcept C55493867 @default.
• W2103188542 hasConcept C71924100 @default.
• W2103188542 hasConcept C86803240 @default.
• W2103188542 hasConcept C8891405 @default.
• W2103188542 hasConcept C96232424 @default.
• W2103188542 hasConceptScore W2103188542C104317684 @default.
• W2103188542 hasConceptScore W2103188542C121608353 @default.
• W2103188542 hasConceptScore W2103188542C126322002 @default.
• W2103188542 hasConceptScore W2103188542C127561419 @default.
• W2103188542 hasConceptScore W2103188542C203014093 @default.
• W2103188542 hasConceptScore W2103188542C2779786085 @default.
• W2103188542 hasConceptScore W2103188542C502942594 @default.
• W2103188542 hasConceptScore W2103188542C530470458 @default.
• W2103188542 hasConceptScore W2103188542C55493867 @default.
• W2103188542 hasConceptScore W2103188542C71924100 @default.
• W2103188542 hasConceptScore W2103188542C86803240 @default.
• W2103188542 hasConceptScore W2103188542C8891405 @default.
• W2103188542 hasConceptScore W2103188542C96232424 @default.
• W2103188542 hasIssue "2" @default.
• W2103188542 hasLocation W21031885421 @default.
• W2103188542 hasLocation W21031885422 @default.
• W2103188542 hasLocation W21031885423 @default.
• W2103188542 hasLocation W21031885424 @default.
• W2103188542 hasOpenAccess W2103188542 @default.
• W2103188542 hasPrimaryLocation W21031885421 @default.
• W2103188542 hasRelatedWork W1822510418 @default.
• W2103188542 hasRelatedWork W2009578901 @default.
• W2103188542 hasRelatedWork W2016159668 @default.
• W2103188542 hasRelatedWork W2060393770 @default.
• W2103188542 hasRelatedWork W2977567559 @default.

• next